Key result
Serum cystatin-C levels were significantly elevated in patients with ischemic heart disease compared to healthy controls (1.62 vs 0.38 µg/L, p<0.0001), with the highest levels observed in diabetic patients.
Why the study?
Is fasting serum cystatin-C elevated in diabetic and non-diabetic patients with ischemic heart disease compared to healthy controls?
Case-Control (n=170)
No
Is fasting serum cystatin-C elevated in diabetic and non-diabetic patients with ischemic heart disease compared to healthy controls?
Absolute Event Rate: 1.62% vs 0.38%
p-value: p=<0.0001
Serum cystatin-C is significantly elevated in patients with ischemic heart disease, particularly those with concurrent diabetes, suggesting its potential utility as a prognostic biomarker.
Cystatin-C elevation does not yet support practice change in ischemic heart disease; leaves open its prognostic value in diabetic patients.
Background:recent data indicate the prevalence of cardiovascular disease in patientswith high cystatin-C level;it can be used as a good predictor for assessment of mortality in cardiovascular diseases regardless of the status of renal function.Patients and methods: Onehundred twenty (120) patients with ischemic heart disease admitted to this study at Baghdad teaching hospital for the period from January 2011 to September2011,Those patients categorized into two groups (60) diabetic and (60) non diabetic in comparison to fifty healthy control.Fasting serum cystatin-C was measured in all patients and controls.Results: The level of serum cystatin-C, in diabetic patients with ischemic heart disease was (2.05±0.55 μg/L). Its level in non diabetic patients with ischemic heart disease was (1.19±0.59 μg/L)both were significantly higher(p<0.001)than its level in healthy control(0.38±0.062 μg/L).Conclusion:Cystatin-C is good prognostic biomarker in patients with ischemic heart disease with or without diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Mutlak et al. (2012) conducted a case-control in Ischemic heart disease (n=170). Ischemic heart disease vs. Healthy controls was evaluated on Fasting serum cystatin-C level (p=<0.0001). Serum cystatin-C levels were significantly elevated in patients with ischemic heart disease compared to healthy controls (1.62 vs 0.38 µg/L, p<0.0001), with the highest levels observed in diabetic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: